Small Cell Lung Cancer - Epidemiology Forecast to 2029

Small Cell Lung Cancer - Epidemiology Forecast to 2029

Summary

SCLC accounts for 15% of all lung cancers. SCLC is an aggressive form of lung cancer where approximately 60-70% of patients already have distant metastasis at presentation. SCLC is predominant in elderly populations that are heavy smokers, and the risk of SCLC is proportional to duration and frequency of smoking. Signs and symptoms of SCLC include cough, chest pain, hemoptysis, dyspnea, and weight loss. SCLC has a very poor survival rate, as most of the deaths occur within a year of diagnosis.

GlobalData epidemiologists used age- and sex-specific diagnosed incidence and prevalence rates to forecast the diagnosed incident and prevalent cases, taking into account the significant relationship between age and SCLC incidence. GlobalData epidemiologists applied country-specific incidence rates of SCLC, wherever available, to each countrys population to obtain the number of estimated diagnosed incident cases.

The following data describes epidemiology of SCLC cases. In 2019, the 8MM had 180,370 diagnosed incident cases of SCLC. This is expected to increase to 243,116 diagnosed incident cases by 2029, at an Annual Growth Rate (AGR) of 3.48%. This increase is partly attributed to the moderately rising trend in incidence in the 8MM, combined with underlying demographic changes in the respective markets. In the 8MM, the five-year diagnosed prevalent cases of SCLC will increase from 153,744 cases in 2019 to 209,944 cases in 2029, at an AGR of 3.66%. The early diagnosis and development of more effective therapies, particularly for elderly patients, would improve survival from SCLC.

Scope

- Small Cell Lung Cancer(SCLC) Epidemiology Report provides an overview of the risk factors and global trends of SCLC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Urban China).
- This report also includes a 10-year epidemiological forecast for the following segmentations in all ages across the 8MM: diagnosed incident cases of SCLC segmented by sex and age (18-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years and older); diagnosed five-year prevalent cases SCLC; diagnosed incident cases of SCLC by cancer staging (limited and extensive); and diagnosed incident cases of SCLC by SLFN11 biomarker.
- The SCLC Epidemiology Report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The SCLC Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global SCLC market.
- Quantify patient populations in the global SCLC market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the SCLC cancer stages that present the best opportunities for SCLC therapeutics in each of the markets covered.
- Understand magnitude of SCLC market by biomarker.

1
1.1 List of Tables
1.2 List of Figures
2 Small Cell Lung Cancer: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for SCLC, 2019-2029
3.5.1 Diagnosed Incident Cases of SCLC
3.5.2 Sex-Specific Diagnosed Incident Cases of SCLC
3.5.3 Age-Specific Diagnosed Incident Cases of SCLC
3.5.4 Diagnosed Incident Cases of SCLC by Stage at Diagnosis
3.5.5 Five-Year Diagnosed Prevalent Cases of SCLC
3.5.6 Diagnosed Incident Cases of SLFN11-Positive SCLC
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 COVID-19 Impact
3.6.3 Limitations of the Analysis
3.6.4 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.3 Epidemiologist
4.3.1 Reviewers
4.3.2 Global Director of Therapy Analysis and Epidemiology
4.3.3 Global Head and EVP of Healthcare Operations and Strategy
4.4 About GlobalData
4.5 Contact Us
4.6 Disclaimer

List Of Tables

Table 1: Summary of Newly Added Data Types and Countries
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbidities for SCLC

List Of Figures

Figure 1: 8MM, Diagnosed Incident Cases of SCLC, Both Sexes, Ages 18 Years, 2019 and 2029
Figure 2: 8MM, Diagnosed Incidence of SCLC, Men, Ages 18 Years, 2009-2029
Figure 3: 8MM, Diagnosed Incidence of SCLC, Women, Ages 18 Years, 2009-2029
Figure 4: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of SCLC
Figure 5: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of SCLC by Stage at Diagnosis
Figure 6: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of SCLC
Figure 7: 8MM, Sources Used to Forecast the SLFN11 Biomarker of SCLC
Figure 8: 8MM, Diagnosed Incident Cases of SCLC, Both Sexes, Ages 18 Years, N, 2019
Figure 9: 8MM, Diagnosed Incident Cases of SCLC, by Sex, Ages 18 Years, N, 2019
Figure 10: 8MM, Diagnosed Incident Cases of SCLC by Age, Both Sexes, N, 2019
Figure 11: 8MM, Diagnosed Incident Cases of SCLC by Stage at Diagnosis, Ages 18 Years, Both Sexes, N, 2019
Figure 12: 8MM, Five-Year Diagnosed Prevalent Cases of SCLC, Ages 18 Years, Both Sexes, N, 2019
Figure 13: 8MM, Diagnosed Incident Cases of SLFN11-Positive SCLC, Ages 18 Years, Both Sexes, N, 2019 and 2029

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available